Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab

References

• Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol 2004;31:128–136.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38–47.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009;19:12–16.
   PubMed Web of Science ®Google Scholar
• Hockel M, Schlenger K, Aral B, . Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–4515.
   PubMed Web of Science ®Google Scholar
• Zhong H, De Marzo AM, Laughner E, . Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830–5835.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, . Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192–1202.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–732.
   PubMed Web of Science ®Google Scholar
• Theodoropoulos VE, Lazaris A, Sofras F, . Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004;46:200–208.
   PubMed Web of Science ®Google Scholar
• Rasheed S, Harris AL, Tekkis PP, . Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 2009;100:1666–1673.
   PubMed Web of Science ®Google Scholar
• Kim JA, Kim SJ, Do IG, . Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?Leuk Lymphoma 2011;52:205–213.
   PubMed Web of Science ®Google Scholar
• Evens AM, Sehn LH, Farinha P, . Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010;28: 1017–1024.
   PubMed Web of Science ®Google Scholar
• Lidgren A, Hedberg Y, Grankvist K, . The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005;11:1129–1135.
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Li J, Zhang X, . Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004;64:1765–1772.
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L, . Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000;96:3712–3718.
   PubMed Web of Science ®Google Scholar
• Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005;17:611–616.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88: 1474–1480.
   PubMed Web of Science ®Google Scholar
• Hoogsteen IJ, Marres HA, Bussink J, . Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 2007;29: 591–604.
   PubMed Web of Science ®Google Scholar
• Hui EP, Chan AT, Pezzella F, . Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Res 2002;8:2595–2604.
   PubMed Web of Science ®Google Scholar
• Xueguan L, Xiaoshen W, Yongsheng Z, . Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol (R Coll Radiol) 2008;20:606–612.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Pezzella F, . Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 2008;26:219–224.
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Tibshirani RJ, . Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008;88:38–47.
   PubMed Web of Science ®Google Scholar
• Gray MJ, Zhang J, Ellis LM, . HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005;24:3110–3120.
   PubMed Web of Science ®Google Scholar
• Bonello S, Zahringer C, BelAiba RS, . Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 2007;27:755–761.
   PubMed Web of Science ®Google Scholar
• Gupta D, Crosby ME, Almasan A, . Regulation of CD20 expression by radiation-induced changes in intracellular redox status. Free Radic Biol Med 2008;44:614–623.
   PubMed Web of Science ®Google Scholar
• Jak M, van Bochove GG, van Lier RA, . CD40 stimulation sensitizes CLL cells to rituximab-induced cell death. Leukemia 2011;25:968–978.
   PubMed Web of Science ®Google Scholar
• Bos R, van Diest PJ, van der Groep P, . Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene 2003;22:8948–8951.
   PubMed Web of Science ®Google Scholar
• Ruan J. Antiangiogenic therapies in non-Hodgkin's lymphoma. Curr Cancer Drug Targets 2011;11:1030–1043.
   PubMed Web of Science ®Google Scholar